# Citizens, Inc.: financial statements, quarterly

CIA · NYSE · CIK 24090 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cia.md) · [Financials](/companies/cia/financials.md) · [Filings](/companies/cia/filings.md) · [Insiders](/companies/cia/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cia/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [59.4](/filings/0000024090-25-000018.md) | [66.8](/filings/0000024090-25-000018.md) | [57.7](/filings/0000024090-26-000011.md) | [62.1](/filings/0000024090-26-000011.md) | [61.7](/filings/0000024090-26-000011.md) | [63.5](/filings/0000024090-26-000011.md) | [55.7](/filings/0000024090-26-000027.md) | [65.1](/filings/0000024090-26-000043.md) | [62.8](/filings/0000024090-26-000011.md) | [72.1](/filings/0000024090-26-000011.md) | [59.7](/filings/0000024090-26-000027.md) | [60.4](/filings/0000024090-26-000043.md) |
| Income tax | $m | [1.9](/filings/0000024090-25-000018.md) | [(2.0)](/filings/0000024090-25-000018.md) | [0.4](/filings/0000024090-26-000011.md) | [(0.7)](/filings/0000024090-26-000011.md) | [0.2](/filings/0000024090-26-000011.md) | [0.1](/filings/0000024090-26-000011.md) | [(0.2)](/filings/0000024090-26-000027.md) | [0.5](/filings/0000024090-26-000043.md) | [2.1](/filings/0000024090-26-000011.md) | [0.5](/filings/0000024090-26-000011.md) | [0.1](/filings/0000024090-26-000027.md) | [(0.1)](/filings/0000024090-26-000043.md) |
| Net income | $m | [2.7](/filings/0000024090-25-000018.md) | [10.7](/filings/0000024090-25-000018.md) | [4.5](/filings/0000024090-26-000011.md) | [4.0](/filings/0000024090-26-000011.md) | [2.8](/filings/0000024090-26-000011.md) | [3.6](/filings/0000024090-26-000011.md) | [(1.6)](/filings/0000024090-26-000043.md) | [6.5](/filings/0000024090-26-000043.md) | [2.4](/filings/0000024090-26-000011.md) | [7.3](/filings/0000024090-26-000011.md) | [2.3](/filings/0000024090-26-000043.md) | [(0.4)](/filings/0000024090-26-000043.md) |

- Revenue: us-gaap:Revenues
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.8](/filings/0000024090-23-000109.md) | [27.0](/filings/0000024090-25-000018.md) | [23.2](/filings/0000024090-24-000088.md) | [26.3](/filings/0000024090-24-000141.md) | [32.4](/filings/0000024090-24-000174.md) | [29.3](/filings/0000024090-26-000011.md) | [18.4](/filings/0000024090-25-000063.md) | [22.7](/filings/0000024090-25-000117.md) | [23.1](/filings/0000024090-25-000124.md) | [23.0](/filings/0000024090-26-000043.md) | [18.5](/filings/0000024090-26-000027.md) | [17.0](/filings/0000024090-26-000043.md) |
| Total assets | $m | [1,565](/filings/0000024090-23-000109.md) | [1,669](/filings/0000024090-25-000018.md) | [1,666](/filings/0000024090-25-000063.md) | [1,662](/filings/0000024090-25-000117.md) | [1,736](/filings/0000024090-25-000124.md) | [1,685](/filings/0000024090-26-000011.md) | [1,702](/filings/0000024090-25-000063.md) | [1,713](/filings/0000024090-25-000117.md) | [1,742](/filings/0000024090-25-000124.md) | [1,755](/filings/0000024090-26-000043.md) | [1,740](/filings/0000024090-26-000027.md) | [1,752](/filings/0000024090-26-000043.md) |
| Total liabilities | $m | [1,412](/filings/0000024090-23-000109.md) | [1,497](/filings/0000024090-25-000018.md) | [1,470](/filings/0000024090-24-000088.md) | [1,471](/filings/0000024090-24-000141.md) | [1,528](/filings/0000024090-24-000174.md) | [1,475](/filings/0000024090-26-000011.md) | [1,484](/filings/0000024090-25-000063.md) | [1,483](/filings/0000024090-25-000117.md) | [1,517](/filings/0000024090-25-000124.md) | [1,520](/filings/0000024090-26-000043.md) | [1,501](/filings/0000024090-26-000027.md) | [1,517](/filings/0000024090-26-000043.md) |
| Shareholders' equity | $m | [153](/filings/0000024090-24-000174.md) | [172](/filings/0000024090-26-000011.md) | [195](/filings/0000024090-25-000124.md) | [191](/filings/0000024090-25-000124.md) | [208](/filings/0000024090-25-000124.md) | [210](/filings/0000024090-26-000043.md) | [218](/filings/0000024090-26-000043.md) | [229](/filings/0000024090-26-000043.md) | [226](/filings/0000024090-25-000124.md) | [235](/filings/0000024090-26-000043.md) | [239](/filings/0000024090-26-000043.md) | [235](/filings/0000024090-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [3.2 d](/filings/0000024090-24-000174.md) | [6.6 d](/filings/0000024090-25-000018.md) | [6.8](/filings/0000024090-25-000063.md) | [4.6 d](/filings/0000024090-25-000117.md) | [9.7 d](/filings/0000024090-25-000124.md) | [10.8 d](/filings/0000024090-26-000011.md) | [0.7](/filings/0000024090-26-000027.md) | [3.5 d](/filings/0000024090-26-000043.md) | [4.7 d](/filings/0000024090-25-000124.md) | [9.1 d](/filings/0000024090-26-000011.md) | [(0.3)](/filings/0000024090-26-000027.md) | [2.0 d](/filings/0000024090-26-000043.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000024090-24-000174.md) | [0.2 d](/filings/0000024090-25-000018.md) | [0.1](/filings/0000024090-25-000063.md) | [0.1 d](/filings/0000024090-25-000117.md) | [0.4 d](/filings/0000024090-25-000124.md) | [0.1 d](/filings/0000024090-26-000011.md) | [0.1](/filings/0000024090-26-000027.md) | [0.2 d](/filings/0000024090-26-000043.md) | [0.1 d](/filings/0000024090-25-000124.md) | [0.1 d](/filings/0000024090-26-000011.md) | [0.3](/filings/0000024090-26-000027.md) | [0.0 d](/filings/0000024090-26-000043.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

Shares outstanding: 50,643,108 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0000024090-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.